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regimen against the hyper-virulent 
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Steven G. Reed3, Sang-Nae Cho1, Sang-Jun Ha  2 & Sung Jae Shin1*
Since ID93/GLA-SE was developed as a targeted BCG-prime booster vaccine, in the present study, we 
evaluated the protective efficacy of ID93/GLA-SE as a boost to a BCG-prime against the hypervirulent 
Mycobacterium tuberculosis (Mtb) K challenge to provide further information on the development and 
application of this vaccine candidate. Boosting BCG with the ID93/GLA-SE vaccine significantly reduced 
bacterial burden at 16 weeks post-challenge while the BCG vaccine alone did not confer significant 
protection against Mtb K. The pathological analysis of the lung from the challenged mice also showed 
the remarkably protective boosting effect of ID93/GLA-SE on BCG-immunised animals. Moreover, 
qualitative and quantitative analysis of the immune responses following ID93/GLA-SE-immunisation 
demonstrated that ID93/GLA-SE was able to elicit robust and sustained Th1-biased antigen-specific 
multifunctional CD4+ T-cell responses up to 16 weeks post-challenge as well as a high magnitude of an 
antigen-specific IgG response. Our findings demonstrate that the ID93/GLA-SE vaccine candidate given 
as a BCG-prime boost regimen confers a high level of long-term protection against the hypervirulent 
Mtb Beijing infection. These findings will provide further and more feasible validation for the potential 
utility of this vaccine candidate particularly in East-Asian countries, with the predominance of the 
Beijing genotype, after BCG vaccination.
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the number one infectious disease causing 
human death in the world. In 2017, TB ranked as one of the top ten killers, causing an estimated 10 million new 
cases with 1.6 million people having died of TB disease. In addition, approximately 1.7 billion people, equivalent 
to roughly 23% of the global population, are estimated to harbor a latent TB infection (LTBI) and therefore carry 
the risk of progressing to active TB disease during their lifetime. The global emergence and spread of Mtb strains 
resistant to one or more front-line TB drugs also contributes to the challenges of treating these burdensome 
infections1.
The WHO End TB Strategy, has put forth priorities for Mtb control with the ambitious target of reducing 
global TB disease burden. However, subsequent reporting on TB disease trends are to date inadequate to meet 
these goals1. Among important TB control measures, the development of novel more effective TB vaccines is one 
such measure urgently needed to archive this goal.
In 2018, the clinical efficacy trials of two TB multi-antigenic subunit vaccines have demonstrated promis-
ing results and have helped to advance the experimental design strategies in the TB vaccine field and candi-
date pipeline. First, the H4:IC31 candidate was evaluated as a prevention of infection (prophylactic) strategy 
in high-transmission risk adolescents2. In this trial, the H4:IC31 vaccination reduced the rate of sustained 
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QuantiFERON-TB Gold In-tube assay conversion, which may reflect sustained Mtb infection, with an efficacy of 
30.5% along with no serious adverse events. Second, the M72/AS01E vaccine candidate was evaluated as a preven-
tion of TB disease trial in Mtb-infected, healthy adults3.
Interestingly, the two subunit vaccine candidates mentioned above have three common properties; (1) 
multi-antigenic protein vaccine produced as a single fusion protein, (2) formulated in their own unique adju-
vants, and (3) evaluated in Mycobacterium bovis Bacillus Calmette–Guérin (BCG)-vaccinated healthy popula-
tions in TB endemic regions, mainly in South African countries. In addition, as with most vaccine candidates, 
the two subunit vaccines were evaluated and optimised in a variety of animal models prior to advancing into 
clinical trials4–9. Moreover, both vaccine candidates effectively boosted a BCG-induced immune response with 
the maintenance of a long-term protection and persistent Th1-biased multifunctional CD4+ T-cell responses in 
preclinical TB models4,9.
Likewise, novel subunit vaccine candidate ID93, which has similar properties as the two above-mentioned 
vaccine candidates including a multi-antigenic fusion protein combined with a synthetic TLR4 glucopyranosyl 
lipid adjuvant formulated in a stable oil-in-water emulsion (GLA-SE), has entered into clinical trials. Recently 
reported from a phase 1 clinical trial, an acceptable safety profile and durable Th1-immunogenicity response was 
attributed to ID93/GLA-SE given to previously BCG-vaccinated healthy adults10.
Previously, our group demonstrated that vaccination with the ID93/GLA-SE candidate induces a robust 
reduction of bacterial burden against challenge with the hypervirulent Mtb K/Beijing clinical isolate from a 
TB outbreak in high schools of South Korea11. Protection with this vaccine was characterised by pulmonary 
Th1-polarised T-cell immune responses in head-to-head comparison between BCG and the ID93/GLA-SE 
vaccine in a standard mouse model12. In a separate manuscript, the ID93/GLA-SE vaccine was shown to elicit 
protection against Mtb W/Beijing HN878 and provide long-lived vaccine-specific Th1-type T-cell immunity 
in a standard mouse model13, which also included BCG vaccination as a comparator. These findings support 
the potential use of this vaccine candidate specifically in East-Asian countries where Beijing family strains are 
predominant14. In addition, the Mtb Beijing lineage strains are expanding globally with the massive spread of 
multidrug-resistant TB more rapidly than other lineages15, indicating that evaluation of vaccine candidates 
against the Beijing family in relevant preclinical models is urgently required and may significantly impact global 
health16. Thus, both investigations strengthen the rationale for evaluating the long-lived efficacy of subunit TB 
vaccine candidates, like ID93/GLA-SE, against a clinically relevant hypervirulent Mtb isolate in an accessible 
preclinical animal model.
BCG, the only licensed vaccine against TB, is given to neonates or young children in many countries even 
though variable and waning efficacy of protection against pulmonary TB has been observed across several clin-
ical studies17,18. Nevertheless, recent clinical meta-analyses studies have demonstrated that individuals who are 
relatively naïve to mycobacterial exposure prior to BCG vaccination are associated withenhanced efficacy end-
points19, and significant BCG-induced protection against severe disseminated Mtb infection supports its use20. 
In addition, two promising multi-antigenic subunit vaccine candidates, H4:IC31 and M72/AS01E, mentioned 
above2,3, were evaluated as a BCG booster vaccine in clinical trials. Thus, although BCG is unable to eradicate TB 
disease when given alone, we propose that leveraging BCG in a prime-boost regimen may provide a promising 
vaccine strategy for the prevention of TB disease.
The capacity of T-cells to be expanded and differentiated into effector T-cells from central memory T-cells 
in response to BCG stimulation wanes with increased age in healthy children, suggesting that booster vaccines 
should be considered to maintain the antigen-specific T-cells and possibly enhance the duration of protection 
afforded by BCG21. For these reasons, in the current study, we evaluated protective efficacy of ID93/GLA-SE as a 
BCG-prime booster vaccine against Mtb K to provide further and more feasible validation.
Although ID93/GLA-SE TB vaccine candidate is currently under evaluation in human clinical trials and has 
been tested in numerous animal models22–24 to our knowledge, evaluation of this TB vaccine as a boost to a 
BCG-prime in a long-term standard mouse TB model has not been previously reported. For these reasons, in the 
current study, we evaluated protective efficacy of ID93/GLA-SE as a BCG-prime booster vaccine against Mtb K in 
a murine model to provide further and more feasible validation of this subunit vaccine candidate.
Results
Antigen-specific immune responses following ID93/GLA-SE immunisation in BCG-vaccinated 
mice. We previously showed prophylactic efficacy of ID93/GLA-SE vaccine candidate, in the absence of BCG 
priming, where mice exhibited remarkable reduction of bacterial burden in the tested organs in addition to signif-
icantly attenuated lung inflammation following Mtb K infection12. In addition, ex vivo re-stimulation of cells from 
ID93/GLA-SE immunised mice with ID93 produced substantial IFN-γ in both lung and spleen in a dose-depend-
ent manner12. In the present study, we show antigen-specific immune responses including cellular and humoral 
responses in BCG-vaccinated mice followed by immunisation with ID93/GLA-SE, where lung and spleen cells 
were re-stimulated with ID93 or PPD, and immune responses were compared with those of BCG vaccination 
alone control group (Figs 1 and 2, Supplementary Figs S2–S4).
After ex vivo stimulation of lung or spleen cells with ID93, cells from BCG-primed, ID93/GLA-SE boosted 
mice produced statistically significant polyfunctional T-cell responses including increased frequencies and abso-
lute numbers of triple-positive (p < 0.001 for lung and p < 0.01 for spleen) and double-positive (p < 0.005 for lung 
and p < 0.05 for spleen) T-cells producing IFN-γ plus TNF-α and/or IL-2. In contrast, BCG immunised mice 
produced marginal T-cell responses in both organs (Figs 1 and 2). However, no differences in T-cell response 
between BCG-immunised group or in the BCG-primed, ID93/GLA-SE boosted group were detected in response 
to PPD ex vivo stimulation (Supplementary Figs S2 and S3), indicating that T-cell responses following ID93/
GLA-SE immunisation were elicited in an ID93-specific manner prior to Mtb challenge. No increase of multi-
functional CD8+ T-cell response was observed in response to either ID93 or PPD stimulation (data not shown).
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Figure 1. Quantitative and qualitative analysis of antigen-specific multifunctional CD4+ T-cells induced 
by ID93/GLA-SE immunisation in the lung. Four weeks after final immunisation, mice from each group 
(n = 4) were sacrificed, and lung cells were re-stimulated with or without ID93 (1 μg/ml) at 37 °C for 12 hours 
in the presence of GolgiStop and GolgiPlug. (A) The frequencies of ID93-specific IFN-γ+TNF-α+- or IFN-
γ+IL-2+-producing CD4+CD44+ T-cells were determined by intracellular cytokine staining in the lungs of 
each immunised mice as representative dot plots with bar graphs. (B) ID93-stimulated lung cells from each 
immunised group were evaluated based on the percentage of total CD4+CD44+ T-cells with different patterns of 
cytokine production and described as bar graphs (upper). The pie charts summarise the fractions of triple (3+, 
purple), double (2+, light jade), and single (1+, grey) CD4+CD44+ T-cell producers of IFN-γ, TNF-α and IL-2 
in each immunised group (lower). (C) The actual number of ID93-specific multifunctional T-cells among total 
CD4+CD44+ T-cells from each immunised group is represented as bar graphs (upper). The mean number of 
cytokine-positive cells is displayed as pie charts with multiple colour fractions, and the number of rest population 
in total CD4+CD44+ T-cells is described as grey fraction in the pie charts (lower). The experimental results are 
presented as the mean ± SD from 4 mice from each group. Statistically significant differences between the groups 
were determined using an unpaired Student’s t test. n.s.; not significant, *p < 0.05, **p < 0.01, ***p < 0.001, and 
****p < 0.0001 comparing the BCG immunised mice and BCG-primed ID93/GLA-SE boosted mice.
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Figure 2. Induction of antigen-specific multifunctional T-cells based on quality and magnitude in spleen of 
ID93/GLA-SE-immunised mice. Similar to lung cells from each immunised mice (n = 4) depicted in Fig. 1, 
spleen cells were restimulated with ID93 (1 μg/ml) at 37 °C for 12 hours in the presence of GolgiStop and 
GolgiPlug. (A) The frequencies of ID93-specific IFN-γ+TNF-α+- or IFN-γ+IL-2+-producing CD4+CD44+ 
T-cells were determined by intracellular cytokine staining in the spleens of each immunised mice as 
representative dot plots with bar graphs. (B) ID93-stimulated spleen cells from each immunised group were 
evaluated based on the percentage of total CD4+CD44+ T-cells with different patterns of cytokine production 
and described as bar graphs (2B, upper). The pie charts summarise the fractions of triple (3+, purple), double 
(2+, light jade), and single (1+, grey) CD4+CD44+ T-cell producers of IFN-γ, TNF-α and IL-2 in each 
immunised group (2B, lower). (C) The actual number of ID93-specific multifunctional T-cells among total 
CD4+CD44+ T-cells from each immunised group was represented as the bar graphs (2C, upper). The mean 
number of cytokine-positive cells are displayed as pie charts with multiple colour fractions, and the number 
of rest population in total CD4+CD44+ T-cells was described as grey fraction in the pie charts (2 C, lower). 
The experimental results are presented as the mean ± SD from 4 mice from each group. Statistically significant 
differences between the groups were determined using an unpaired Student’s t test. *p < 0.05, **p < 0.01, and 
***p < 0.001 comparing the BCG immunised mice and BCG-primed ID93/GLA-SE boosted mice.
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Next, four weeks after the final immunisation antigen-specific antibody responses to PPD or ID93 were 
assessed in each group to determine whether immunisation elicited humoral responses. The ID93-specific IgG 
responses, including IgG1 and IgG2c, were significantly pronounced in the BCG-primed ID93/GLA-SE–boosted 
Figure 3. Long-term protective efficacy against the hypervirulent Mtb K strain using a prime/boost regimen 
with BCG and the ID93/GLA-SE vaccine candidate. (A) CFUs in the lungs and spleens of each group at 16 
weeks post infection was analysed by enumerating the viable bacteria. (B) The superior lobes of the right lung of 
each immunised mouse were analysed using H&E staining (3B, upper left and bottom), and representative lung 
lobes were depicted as gross images (3B, upper right) at 16 weeks after Mtb K infection (1X: Scale bar = 2.0 mm, 
10X: Scale bar = 0.5 mm). (C) The experimental results indicate the percentage of inflamed area and the size of 
lesions in the lung, and are described through box and whisker plots. Data from each immunised group (n = 8) 
at designated time point are described. One-way ANOVA followed by Tukey’s multiple comparison test was 
used to evaluate the significance. n.s.: not significant, *p < 0.05, **p < 0.01, and ***p < 0.001.
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Figure 4. Long-lasting induction of antigen-specific polyfunctional CD4+ T-cell responses in the lungs of BCG 
primed, ID93/GLA-SE boosted mice following infection with the Mtb Beijing strain K. The mice in each group 
were sacrificed at 16 weeks post-infection, and lung cells were stimulated ex vivo with ID93 (1 μg/ml) at 37 °C 
for 12 hours in the presence of GolgiStop and GolgiPlug. (A) Upon stimulation with the ID93, the frequencies 
of Ag-specific CD4+CD44+ T-cells co-producing IFN-γ+TNF-α+ or IFN-γ+IL-2+ in the lung cells from each 
immunised group were evaluated using flow cytometry and described as representative dot plots and bar 
graphs. (B) ID93-stimulated lung cells from each immunised group were evaluated based on the percentage 
of total CD4+CD44+ T-cells with different patterns of cytokine production and described as bar graphs (4B, 
upper). The pie charts summarise the fractions of triple (3+, purple), double (2+, light jade), and single (1+, 
grey) CD4+CD44+ T-cell producers of IFN-γ, TNF-α and IL-2 in each immunised group (4B, lower). (C) The 
actual number of ID93-specific multifunctional T-cells among total CD4+CD44+ T-cells from each immunised 
group was represented as the bar graphs (4 C, upper). The mean number of cytokine-positive cells are displayed 
as pie charts with multiple colour fractions, and the number of rest population in total CD4+CD44+ T-cells was 
described as grey fraction in the pie charts (4C, lower). The experimental results are presented as the mean ± SD 
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group compared to the BCG alone group (p < 0.0001) (Supplementary Fig. S4A). Interestingly, PPD-specific 
IgG2c in the sera from the BCG-primed ID93/GLA-SE–boosted group was detected (Supplementary Fig. S4B). 
Thus, these results show that ID93/GLA-SE immunisation in BCG-primed animals strongly elicit ID93-specific 
multifunctional CD4+ T-cell responses both in lung and spleen and elicit a potent antibody response, while BCG 
induced immune responses were limited in response to both antigens.
Long-lasting protective efficacy following challenge with Mtb K in BCG-primed mice boosted 
with the ID93/GLA-SE vaccine candidate. To compare the protective efficacy, in terms of reduction 
in bacterial load in mice, bacterial burdens of each group of mice were analysed at 16 weeks after challenge. 
Bacterial CFU in the lungs of BCG immunised mice showed no significant reduction against Mtb K strain chal-
lenge (Fig. 3A) at 16 weeks post-infection. However, ID93/GLA-SE significantly reduced the number of viable 
bacteria in the lungs compared to the infection control and to BCG only groups 16 weeks after challenge (p < 0.01 
for both infection control and BCG control). The bacterial burden in spleen also showed similar pattern to CFU 
in lungs (Fig. 3A). Overall, the animals receiving ID93/GLA-SE immunisation following a BCG-prime showed 
long-term protective efficacy against K strain challenge in terms of bacterial reduction while BCG vaccination 
did not (Fig. 3A).
Reduced lung inflammation following challenge with Mtb K in BCG-primed, ID93/GLA-SE 
boosted mice. One characteristic of Mtb K infection in C57BL/6 mice is the induction of exacerbated lung 
pathology 8 weeks after infection compared to Mtb H37Rv25. To evaluate protection against the extensive lung 
inflammation observed following infection with Mtb K, lungs were harvested from mice immunised with ID93/
GLA-SE vaccination following priming with BCG, and lung pathology was assessed. To measure the extent of 
lung inflammation, histological preparations from each mouse were stained with H&E and the affected areas of 
inflammation relative to the total lung area were analysed.
Compared to the infection control and BCG-vaccination group, mice primed with BCG and boosted with 
ID93/GLA-SE had remarkably decreased granuloma-like lesions and reduced cellularity and size of the lungs 
when examined by gross pathology (Fig. 3B). Interestingly, the BCG-primed, ID93/GLA-SE boosted immuni-
sation group showed significantly reduced inflammation compared to the infection control group (p < 0.001 
for inflamed area percentage and p < 0.05 for inflamed area legions) and BCG-vaccination group (p < 0.05 for 
inflamed area percentage and p < 0.05 for inflamed area legions) in terms of inflammatory areas impacting the 
lung (Fig. 3C). Thus, ID93/GLA-SE immunisation conferred prevention of severe and extensive lung inflamma-
tion compared to that observed following BCG vaccination against Mtb K strain infection.
Long-term maintenance of antigen-specific CD4+ multifunctional Th1 responses after Mtb 
challenge in BCG-primed, ID93/GLA-SE boosted mice. We recently reported that durable protection 
of ID93/GLA-SE immunisation-induced anti-TB immunity was correlated with the sustained multifunctional 
CD4+ T-cell-mediated Th1 immune response after Mtb challenge12,13. To determine whether ID93-specific Th1 
responses persisted in the context of the BCG prime, ID93/GLA-SE boosting strategy, we measured immune 
responses in the lungs of mice after Mtb K strain challenge (Figs 4 and 5). The frequency of ID93-specific triple 
positive (p < 0.0001 for lung and p < 0.001 for spleen) and double positive (p < 0.001 for lung and p < 0.01 for 
spleen) multifunctional CD4+ T-cells in the lung and spleen of mice in the BCG-primed, ID93/GLA-SE boosted 
group was maintained at 16 weeks after challenge with Mtb K (Figs 4 and 5). For PPD stimulation, BCG-primed 
immune responses seemed to be especially boosted in the lungs, not the spleens, by ID93/GLA-SE vaccination 
as evidenced by increased frequency of PPD-specific triple positive (p < 0.0001 for lung) and double positive 
(p < 0.001 for lung) multifunctional CD4+ T-cells (Supplementary Figs S5 and S6).
Next, we investigated cytokine profiles in the lungs and spleens after re-stimulation with ID93 or PPD to 
determine whether Th1-mediated responses were maintained (Fig. 6 and Supplementary Fig. S7). Th1-associated 
cytokines including IFN-γ, TNF-α, and IL-2 but not Th2 cytokines, IL-4 and IL-10, were remarkably induced 
in the lungs from the BCG-primed ID93/GLA-SE boosted group in response to both ID93 (p < 0.0001 for all 
Th1-associated cytokines) and PPD ex vivo stimulation (p < 0.0001 for IFN-γ, p < 0.001 for TNF-α, and p < 0.05 for 
IL-2, respectively) (Fig. 6). Interestingly, IL-17A was induced only in the group that received the BCG-prime ID93/
GLA-SE boost regimen in response to ID93 (Fig. 6A). No differences in IFN-γ or TNF-α production was detected 
between the BCG-vaccination group and BCG-prime ID93/GLA-SE boosted group in the spleen in response 
to either ID93 or PPD stimulation (Supplementary Figs S7A,B). Expression of IL-2, however was increased in 
response to ID93 in the BCG prime ID93/GLA-SE boosted group (p < 0.05) (Supplementary Fig. S7A).
Discussion
In the present study, the long-term protective effect of the ID93/GLA-SE vaccine candidate was evaluated against 
the Beijing family strain, Mtb K, in a BCG prime-boost regimen. The protective immune response against 
the Mtb K strain, induced by this vaccine regimen, was characterised by a durable Th1-biased host response 
including antigen-specific CD4+ T-cells concomitantly producing IFN-γ, TNF-α, and IL-2 in both the lung 
and spleen (Figs 1 and 2) and potentially due to a Th1-biased ID93- and PPD-specific IgG2c humoral response 
(Supplementary Fig. S4). The effective boosting property of the ID93/GLA-SE vaccine within BCG-immunised 
from 8 mice from each group. Statistically significant differences between the groups were determined using 
an unpaired Student’s t test. n.s.; not significant, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 
comparing the BCG immunised mice and BCG-primed ID93/GLA-SE boosted mice.
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Figure 5. Long-lasting induction of antigen-specific polyfunctional CD4+ T-cell responses in the spleens of 
BCG primed, ID93/GLA-SE boosted mice following infection with the Mtb Beijing strain K. The prepared 
splenocytes were re-stimulated similarly to the lung cells. (A) Upon stimulation with the ID93, the frequencies 
of Ag-specific CD4+CD44+ T-cells co-producing IFN-γ+TNF-α+ or IFN-γ+IL-2+ in the spleen cells from 
each immunised group were evaluated using flow cytometry and described as representative dot plots and bar 
graphs. (B) ID93-stimulated spleen cells from each immunised group were evaluated based on the percentage 
of total CD4+CD44+ T-cells with different patterns of cytokine production and described as bar graphs (5B, 
upper). The pie charts summarise the fractions of triple (3+, purple), double (2+, light jade), and single (1+, 
grey) CD4+CD44+ T-cell producers of IFN-γ, TNF-α and IL-2 in each immunised group (5B, lower). (C) The 
actual number of ID93-specific multifunctional T-cells among total CD4+CD44+ T-cells from each immunised 
group was represented as the bar graphs (5C, upper). The mean number of cytokine-positive cells are displayed 
as pie charts with multiple colour fractions, and the number of rest population in total CD4+CD44+ T-cells was 
described as grey fraction in the pie charts (5C, lower). The experimental results are presented as the mean ± SD 
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mice was supported by a decrease in bacterial counts within the lung and spleen (Fig. 3A). Strikingly, excessive, 
irregular, and advanced granulomatous inflammation of lung from the infection control and BCG-vaccination 
groups were shown, whereas small, rounded and contained granulomas were found in the lung of mice vaccinated 
in mice received with BCG-priming boosting followed by ID93/GLA-SE immunisation (Fig. 3B). Although the 
ID93/GLA-SE vaccine candidate has been evaluated in many pre-clinical animal models, including a guinea pig 
model where ID93/GLA-SE was administered as a booster against the reference strain Mtb H37Rv12,13,23, this is 
the first study to evaluate the boosting effect of this vaccine candidate against a Beijing family strain of Mtb in 
BCG-immunised mice. The ID93/GLA-SE vaccine, once approved for use, would be particularly beneficial in 
East-Asian countries where this Beijing genotype is prevalent.
In our previous study, the ID93/GLA-SE vaccine induced protective efficacy when given as a prophylactic vac-
cine against Mtb K strain infection12, but the protection was less robust compared to the BCG vaccine. However, 
the improved potential of ID93/GLA-SE as a booster to the BCG vaccine in a prophylactic setting, not only 
reported in a guinea pig model23 but also shown in this study, suggests that the subunit vaccine is capable of 
re-stimulating the protective immunity upon BCG vaccination against infection with Mtb (Figs. 3, 4 and 5).
In fact, prior studies have shown that BCG vaccine efficacy is dependent on the infectious Mtb strain type26,27. 
The clinical isolate in South Korea, Mtb K, is a representative Beijing family strain from a TB outbreak in South 
Korean high schools11, where most of the students had previously received the BCG vaccine. The infectivity and 
pathogenicity of the virulent clinical Mtb K isolate has been studied in mice to characterise the differences com-
pared to a standard Mtb H37Rv isolate25. In particular, W/Beijing Mtb strains exhibit an increased virulent phe-
notype displayed by faster growth, dampened protective Th1 cellular immune responses, and a higher relapse rate 
than the H37Rv strain in vivo due in part to an expansion of CD4+CD25+Foxp3+ regulatory T-cells compared to 
the H37Rv strain25,27. Moreover, BCG-efficacy against W/Beijing strains of Mtb wanes over time in animal mod-
els27 mimicking human responses to the vaccine.
Although the lack of reliable correlates of protection for TB makes a go/no-go decision for the advance-
ment of TB vaccines difficult, the three multi-antigenic subunit vaccines, already in clinical development (M72/
AS01E, H4:IC31, and ID93/GLA-SE), have commonly shown significant induction of Th1-polarised CD4+ T-cell 
responses characterised by the production of antigen-specific IFN-γ, TNF-α, and IL-228. Furthermore, these 
vaccines induce protective efficacy in different animal models, measured by reduction in both bacterial CFU and 
lung inflammation4,9,12,29. The induction of antigen-specific CD4+ Th1 cellular responses after vaccination have 
therefore supported proof-of-concept for vaccine evaluation in Phase 1 clinical trials10,30–34.
In this study, significant induction of Th1-polarised Ag-specific multifunctional CD4+ T-cell responses and 
marked increase of Ag-specific humoral response were observed in BCG-vaccinated mice immunised with ID93/
GLA-SE (Figs 1, 2 and supplementary Fig. S4). The immunisation conferred long-term protection against the 
virulent Mtb K, as evidenced by a significant CFU reduction in the lung and spleen, and by preventing excessive 
lung inflammation (Fig. 3).
It should be noted that long-lasting pulmonary control by prime-boost vaccination with BCG and ID93/
GLA-SE against Mtb infection was accomplished (Fig. 3A). An enhanced level of pulmonary protection com-
pared to that seen in the spleens was observed in the lungs of ID93/GLA-SE-boosted mice. First, the aerosol 
challenge of Mtb may lead to homing of antigen-specific T-cells to the lung engaging effector responses compared 
to the spleen. Secondly, while ID93-specific multifunctional CD4+ T-cells are induced in both the spleens and 
lungs of each immunised mouse prior to Mtb challenge (Figs 1 and 2), a larger number of ID93-responding 
multifunctional CD4+ T-cells appear to be maintained in lungs compared to that observed in the spleens after 
Mtb challenge (Figs 4 and 5). This suggests that the maintenance of ID93-specific multifunctional T-cell popu-
lation, particularly in the lungs for at least 16 weeks post-infection may confer improved protection. Thirdly, a 
significantly higher magnitude of Th1-polarised cytokines such as IFN-γ, IL-2 and TNF-α, not Th2-associated 
cytokines, are induced following the ex vivo stimulation with both ID93 and PPD from cells in the lungs from 
ID93/GLA-SE-boosted mice (Fig. 6), but not in spleen except for IL-2 (Supplementary Fig. S7), which could con-
tribute to better protection in the lung. Fourth, in addition to direct protective pulmonary contribution, boosting 
BCG with ID93/GLA-SE induced antigen-specific antibody responses (Supplementary Fig. S4). Unlike the guinea 
pigs data23, ID93-specific IgG1 and IgG2c responses were not found to be different in the BCG prime/boosted 
mouse study, representing an IgG2c/IgG1 mixed antibody response. Notably, PPD-specific IgG2c responses were 
significantly increased compared to IgG1 responses. This PPD-specific IgG2c biased response may be associated 
with an enhanced Th1-polarised response contributing to improved BCG primed/boosted protection against 
Mtb infection. Lastly, ID93-specific IL-17 production in the lungs was notably observed (Fig. 6A). Recently, the 
protective role of Th17 responses against Mtb has emerged in the literature by controlling Mtb growth and limit-
ing extensive pathology in the lungs during Mtb infection35–41. In fact, IL-17-producing Th17 cells are considered 
to be particularly essential in vaccine-mediated immunity35,42 by rapidly recruiting CD4+IFN-γ+ T-cells to the 
site of infection, leading to earlier control of Mtb35. A previous study has shown that ID93/GLA-SE vaccination 
can elicit Th17 responses when given intranasally but not through intramuscular injection43. Although induced 
tissue-resident Th17 responses do not contribute to the protective efficacy in the murine subunit vaccination 
model43, ID93-specific IL-17 production may contribute to improved vaccine efficacy in animals that received 
ID93/GLA-SE as a boost in the BCG booster murine model which is employed for the first time (Figs 3 and 6). 
Nevertheless, the underlying mechanisms associated with improved protection conferred by BCG-primed ID93/
GLA-SE boosting vaccination remains to be clearly defined.
from 8 mice from each group. Statistically significant differences between the groups were determined using 
an unpaired Student’s t test. n.s.; not significant, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 
comparing the BCG immunised mice and BCG-primed ID93/GLA-SE boosted mice.
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Prior studies have shown that mice immunised with the ID93/GLA-SE candidate vaccine generate a 
Th1-biased response, with antigen-specific polyfunctional CD4+ T-cells. ID93/GLA-SE prophylactic immuni-
sation has led to the protection of mice against challenge with either H37Rv23,44 or a multidrug-resistant TN5904 
Figure 6. Protective cytokine profiles in the lungs of BCG primed, ID93/GLA-SE boosted mice 16 weeks 
following infection with the Mtb Beijing strain K. (A,B) Lung cells from naïve, infected, BCG-immunised and 
BCG-primed ID93/GLA-SE boosted mice (n = 8 mice/group at 16 weeks following infection) were stimulated 
with or without (A) ID93 (1 μg/ml) or (B) PPD (2 μg/ml) at 37 °C for 12 hours, and the supernatant was then 
collected and assayed for cytokines by ELISA. Statistically significant differences between the groups were 
determined using an unpaired Student’s t test. n.s.; not significant, *p < 0.05, ***p < 0.001, and ****p < 0.0001 
comparing the BCG immunised mice and BCG-primed ID93/GLA-SE boosted mice.
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strain of Mtb23. Furthermore, boosting BCG with ID93/GLA-SE conferred long-term protection accompanied 
with ameliorated pathology against TB in guinea pig model23. Considering that promising results of heterolo-
gous prime/boost regimens such as BCG primed followed by boosting with adjuvanted antigens found in BCG 
and/or Mtb45,46, ID93 which is composed of antigens found in both Mtb and BCG could be capable of boosting 
BCG-primed immunity. Based on these results including our study, which strengthen the immunogenicity and 
protective efficacy of ID93/GLA-SE as a BCG booster, there is the potential for use of this vaccine candidate as a 
booster vaccine to improve the waning efficacy of the BCG vaccine. Since vaccination of BCG occurs within the 
first month of birth according to the BCG vaccination policy in South Korea, the efficacy testing of ID93/GLA-SE 
as a booster vaccine is ongoing in humans. Advances towards TB elimination by preventing Mtb transmission 
will require strenuous efforts including prevention of disease, where the impact of this BCG prime, ID93/GLA-SE 
boost vaccine regimen may be especially effective23.
Collectively, the capacity of T-cells to be expanded and differentiated into effector T-cells from central mem-
ory T-cells in response to BCG stimulation wanes with the increase of age in healthy children, suggesting that 
booster vaccines should be considered to maintain the antigen-specific T-cells and possibly enhance the dura-
tion of protection afforded by BCG21. ID93/GLA-SE was able to elicit robust and sustained Th1-biased immune 
responses including antigen-specific multifunctional CD4+ T-cell co-producing IFN-γ, TNF-α, and IL-2 as well 
as a high magnitude of antigen-specific Th1-biased antibodies. Our findings showed that ID93/GLA-SE vaccine 
as a BCG-prime booster confers a high level of long-term protection against the hypervirulent Mtb Beijing infec-
tion. These findings also showcase the potential utility of this vaccine candidate in East-Asian countries with the 
predominance of the Beijing genotype after BCG vaccination.
Methods
Ethics statement. All animal studies were carried out accordingly following the guidelines of the Korean 
Food and Drug Administration (KFDA). The experimental protocols used in this study were reviewed and 
approved by the Ethics Committee and Institutional Animal Care and Use Committee (Permit Number: 2015-
0041) of the Laboratory Animal Research Center at Yonsei University College of Medicine (Seoul, Korea).
Preparation of Mycobacterium spp. Mtb K strain was obtained from the strain collections at the Korean 
Institute of Tuberculosis (KIT, Osong, Chungchungbuk-do, Korea). M. bovis BCG (Pasteur strain 1173P2) was 
kindly provided by Dr. Brosch at the Pasteur Institute (Paris, France). These strains were cultured in Middlebrook 
7H9 broth (Difco Laboratories, Detroit, MI) supplemented with 0.02% glycerol and 10% (vol/vol) oleic 
acid-albumin-dextrose-catalase (OADC, Becton Dickinson, Sparks, MD) for 28 days at 37 °C. Single cell suspen-
sions of each strain were prepared as previously described12.
Animals, immunisation, and challenge protocol. Specific pathogen-free 5-week-old female C57BL/6J 
mice were purchased from Japan SLC, Inc. (Shijuoka, Japan) and strictly maintained under barrier conditions 
in a BL-3 biohazard animal facility at the Yonsei University Medical Research Center. The animals were fed a 
sterile commercial mouse diet and provided with water ad libitum. The mice were monitored daily before and 
after immunisation and Mtb challenge, and none of the mice showed any clinical symptoms or illness during this 
experiment.
Immunisation with ID93 formulated in GLA-SE was performed as previously described12. Briefly, mice were 
immunised with BCG Pasteur 1173P2 via subcutaneous injection (2.0 × 105 CFUs/mouse), then 10 weeks follow-
ing the BCG immunisation, ID93/GLA-SE vaccine (1 μg ID93 antigen formulated in 5 μg of GLA-SE / injection) 
was given as a boost, intramuscularly, three times at 3-week intervals (Supplementary Fig. S1A). Four weeks after 
the final immunisation, the immunised mice were aerogenically challenged with the Mtb K strain as previously 
described12. Aerosol infection was performed using a Glas-Col aerosol apparatus (Terre Haute, IN, USA) adjusted 
to achieve an initial infectious dose of 200 CFUs. At 16 weeks post-challenge, mice from each group were euth-
anised to analyse bacterial load, histopathology, and immune responses including the frequency and number of 
multifunctional T-cells.
Bacterial enumeration and histopathology. At 16 weeks following Mtb challenge, eight mice per group 
were euthanised with CO2, and lungs and spleens were homogenised. The number of viable bacteria was deter-
mined by plating serial dilutions of the organ homogenates onto Middlebrook 7H11 agar (Difco, USA) supple-
mented with 10% OADC (Difco, USA) and amphotericin B (Sigma Aldrich, USA). Colonies were counted after 4 
weeks of incubation at 37 °C. For histopathological analysis, the middle cross-section from entire superior lobes 
of the right lung were stained with hematoxylin and eosin (H&E) and assessed for the severity of inflammation. 
The level of inflammation in the lungs was evaluated using by ImageJ (National Institutes of Health, USA) pro-
gram, as previously described47. Briefly, for quantitative histopathological analysis of H&E staining, all slides were 
scanned using an Olympus BX43 microscope 4 × objective (Olympus Optical Co., Tokyo, Japan), and a patholo-
gist assessed and quantified histopathology in a blinded manner. Each slide image per mouse was evaluated with 
the ToupTek Toup viewer program (Toup View Co., Zhejiang, China) to quantify the total size of the inflamed 
lesions in each mouse. The measured area is presented as mm2.
Flow cytometry and intracellular cytokine staining. Single cell suspensions (1.5 × 106 cells) from 
immunised or Mtb-infected mice were stimulated with PPD (2 μg/ml) or ID93 (1 μg/ml) at 37 °C for 2 hours. 
Then, stimulated-single cell suspensions were further incubated at 37 °C for 10 more hours in the presence of 
both GolgiPlug and GolgiStop (BD Biosciences). PPD was kindly provided by Dr. Michael Brennan at Aeras 
(Rockville, MD, USA). Cells were first washed with 2% FBS containing PBS and blocked with anti-CD16/32 
(BD Biosciences) at 4 °C for 20 min. After the cells were stained with LIVE/DEADTM Fixable Viability Dye 
eFluorTM 780 (ThermoFisher Scientific), and surface stained with Brilliant Violet (BV) 421-conjugated anti-CD4, 
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peridinin chlorophyll (PerCP)-Cy5.5-conjugated anti-CD8, phycoerythrin (PE)-conjugated anti-CD44 (BD 
Biosciences) antibodies at 4 °C for 30 min and were washed. These cells were permeabilised and fixed with the 
Cytofix/Cytoperm kit (BD Biosciences) at 4 °C for 30 min. Then, cells were washed twice with Perm/Wash (BD 
Biosciences) and intracellularly stained with allophycocyanin (APC)-conjugated anti-IFN-γ, BV605-conjugated 
anti-TNF-α and PE-conjugated anti-IL-2 (Biolegend, San Diego, CA, USA) at 4 °C for 30 min. After washing 
three times with Perm/Wash, cells were fixed with IC Fixation buffer (eBioscience). Then, 2% FBS containing 
PBS-resuspended cells were analysed on FACSCanto II (BD Biosciences) using the commercially available 
software program FlowJo (Tree Star, Ashland, OR, USA). Next, the analysed antigen-specific multifunctional 
T-cells were either represented as percentages among total number of CD4+CD44+ T-cells or described as 
actual counts of cytokine-producing cells as bar graphs. Gating strategy for flow cytometry analysis is depicted 
in Supplementary Figure S1B. For pie charts analysis, the values summarise the fractions of triple (3+, purple), 
double (2+, light jade), and single (1+, grey) CD4+CD44+ T-cell producers of IFN-γ, TNF-α and IL-2 in each 
immunised group. The mean number of cytokine-positive cells is displayed as pie charts with multiple colour 
fractions, and the number of the rest of the population in total CD4+CD44+ T-cells was described as a grey frac-
tion in the pie charts.
Antibody titers in serum. 96 well plates were coated with 1 μg/ml of PPD or ID93, and Ag-specific IgG, 
IgG1 and IgG2c responses in serum of immunised mice were measured as previously described48.
Quantification of cytokines. Cytokines in ex vivo-isolated single cells from the lungs and spleens of 
infected mice were analysed by commercial ELISA kits according to the manufacturers’ instructions after stimu-
lation with the PPD (2 μg/ml) or ID93 (1 μg/ml) for 24 hours at 37 °C. The ELISA was used for detecting IFN-γ, 
IL-2, IL-17, TNF-α, IL-4 and IL-10 in the culture supernatant. All ELISA kits were purchased from eBioscience, 
except for the IL-10 ELISA kit (BD Biosciences).
Statistical analysis. Data for all experiments are presented as the mean ± standard deviation (SD). The 
significance of differences between samples was assessed by one-way ANOVA after Tukey’s post-test for multiple 
comparisons in more than three groups or by unpaired t-test in the selected two groups, followed by Shapiro-Wilk 
normality test using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California USA, 
www.graphpad.com). Differences with each value of *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001 were 
considered statistically significant.
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